Maxygen Inc. is not the first company that comes to mind when thinking about extended release drug delivery, but the company is beginning to see dividends from its acquisition last year of a protein modification platform for directed pegylation and gylcosylation. Indeed, last week's deal with InterMune Inc. to develop second generation interferon gamma products essentially could cover the cost of MAXY's $66 million stock purchase of ProFound Pharma A/S, which developed the technology.